Navigation Links
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
Date:9/10/2007

NEW YORK, Sept. 11 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated (Nasdaq: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that a Phase III study of ERBITUX(R) (Cetuximab) in combination with platinum-based chemotherapy (vinorelbine plus cisplatin) met its primary endpoint of increasing overall survival compared with chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC). This large, randomized multi-national study, known as FLEX (First-Line Treatment for Patients with Epidermal growth factor inhibitor (EGFR)-EXpressing Advanced NSCLC) was conducted by Merck KGaA, Darmstadt, Germany and enrolled patients with Stage IIIB or Stage IV NSCLC who had not previously received chemotherapy.

"Based on the FLEX results, ERBITUX is the only member of the class of epidermal growth factor inhibitors to demonstrate survival in the first-line treatment of patients with advanced non-small cell lung cancer. Previous pivotal trials involving other agents targeting EGFR have failed to demonstrate a survival advantage for these patients," stated Eric K. Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems. "These are important results for lung cancer patients and health care professionals treating this devastating disease, since there have been very few treatment advances for lung cancer in recent years."

"Studies have shown that ERBITUX improves overall survival for patients with certain head and neck ca
'/>"/>

SOURCE ImClone Systems Incorporated; Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
5. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
7. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3)
10. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
11. Replidyne Phase II Pediatric Trial Meets Primary Objective
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference 2ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference 3Ascension Orthopedics Hires Key Senior Executives 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Imaging Is Now Easier for the Area 26apos 3Bs Vulnerable Children 48522 1Imaging Is Now Easier for the Area 26apos 3Bs Vulnerable Children 48522 2Imaging Is Now Easier for the Area 26apos 3Bs Vulnerable Children 48522 3San Francisco Symposium Provides Training for Communities Looking to Develop Arts Programs That Unite Generations 48519 1San Francisco Symposium Provides Training for Communities Looking to Develop Arts Programs That Unite Generations 48519 2San Francisco Symposium Provides Training for Communities Looking to Develop Arts Programs That Unite Generations 48519 3NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies 48516 1NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies 48516 2NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies 48516 3NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies 48516 4NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies 48516 5
Breaking Medicine News(10 mins):Health News:Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance 2Health News:Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance 3Health News:Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance 4Health News:The Institute of Women's Health of North America to Offer Free Chlamydia Testing at All Affiliated Campuses – Dr. Abdul Rao 2Health News:The Institute of Women's Health of North America to Offer Free Chlamydia Testing at All Affiliated Campuses – Dr. Abdul Rao 3Health News:Pathological Gambling May Be Successfully Treated With Medications for Substance Addiction 2Health News:Landrieu, Lincoln, Stabenow, Small Business Owners Discuss Positive Impact of Health Reform on Small Businesses 2Health News:Landrieu, Lincoln, Stabenow, Small Business Owners Discuss Positive Impact of Health Reform on Small Businesses 3Health News:Friends Without A Border's First Annual Los Angeles Gala to be Held at Hollywood Roosevelt Hotel With Special Guest Performance by Robin Thicke 2Health News:Friends Without A Border's First Annual Los Angeles Gala to be Held at Hollywood Roosevelt Hotel With Special Guest Performance by Robin Thicke 3